Wang Weisi, Li Qiang, Wei Yufen, Xue Jian, Sun Xiao, Yu Yang, Chen Zhuo, Li Shizhu, Duan Liping
National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, WHO Collaborating Centre for Malaria, Schistosomiasis, and Filariasis, Key Laboratory of Parasitology and Vector Biology of the Chinese Ministry of Health, Shanghai 200025, China; ZJU-ENS Joint Laboratory of Medicinal Chemistry, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, WHO Collaborating Centre for Malaria, Schistosomiasis, and Filariasis, Key Laboratory of Parasitology and Vector Biology of the Chinese Ministry of Health, Shanghai 200025, China.
Int J Parasitol Drugs Drug Resist. 2017 Aug;7(2):191-199. doi: 10.1016/j.ijpddr.2017.03.007. Epub 2017 Apr 2.
Malaria and schistosomiasis are two of the most socioeconomically devastating parasitic diseases in tropical and subtropical countries. Since current chemotherapeutic options are limited and defective, there is an urgent need to develop novel antiplasmodials and antischistosomals. Hemozoin is a disposal product formed from the hemoglobin digestion by some blood-feeding parasites. Hemozoin formation is an essential process for the parasites to detoxify free heme, which is a reliable therapeutic target for identifying novel antiparasitic agents. A series of novel carbazole aminoalcohols were designed and synthesized as potential antiplasmodial and antischistosomal agents, and several compounds showed potent in vitro activities against Plasmodium falciparum 3D7 and Dd2 strains and adult and juvenile Schistosoma japonicum. Investigations on the dual antiparasitic mechanisms showed the correlation between inhibitory activity of β-hematin formation and antiparasitic activity. Inhibiting hemozoin formation was identified as one of the mechanisms of action of carbazole aminoalcohols. Compound 7 displayed potent antiplasmodial (Pf3D7 IC = 0.248 μM, PfDd2 IC = 0.091 μM) and antischistosomal activities (100% mortality of adult and juvenile schistosomes at 5 and 10 μg/mL, respectively) and exhibited low cytotoxicity (CC = 7.931 μM), which could be considered as a promising lead for further investigation. Stoichiometry determination and molecular docking studies were also performed to explain the mode of action of compound 7.
疟疾和血吸虫病是热带和亚热带国家中对社会经济破坏最大的两种寄生虫病。由于目前的化疗选择有限且存在缺陷,迫切需要开发新型抗疟药和抗血吸虫药。疟色素是一些吸血寄生虫消化血红蛋白形成的一种代谢产物。疟色素的形成是寄生虫将游离血红素解毒的一个重要过程,这是鉴定新型抗寄生虫药物的一个可靠治疗靶点。设计并合成了一系列新型咔唑氨基醇作为潜在的抗疟和抗血吸虫药物,几种化合物对恶性疟原虫3D7和Dd2菌株以及日本血吸虫成虫和幼虫表现出强大的体外活性。对双重抗寄生虫机制的研究表明,β-疟原虫血红素形成的抑制活性与抗寄生虫活性之间存在相关性。抑制疟色素形成被确定为咔唑氨基醇的作用机制之一。化合物7表现出强大的抗疟活性(Pf3D7 IC = 0.248 μM,PfDd2 IC = 0.091 μM)和抗血吸虫活性(在5和10 μg/mL时,日本血吸虫成虫和幼虫的死亡率分别为100%),并且细胞毒性较低(CC = 7.931 μM),可被视为进一步研究的一个有前景的先导化合物。还进行了化学计量测定和分子对接研究以解释化合物7的作用模式。